Activating mutations in FLT3, which can occur as tandem duplication (ITD) or tyrosine kinase domain (TKD) mutations, are associated with increased tumor burden and risk of relapse in non-APL AML and are considered to be a negative prognostic marker (47). The gene discussed is FLT3; the disease is acute promyelocytic leukemia.